IMULAN Initiates Feline Leukemia Virus (FeLV) Study

Share Article

IMULAN has initiated additional clinical trials to assess the effects of the first and only approved treatment aid in the United States for feline leukemia virus (FeLV) and feline immunodeficiency virus (FIV or Feline AIDS).

IMULAN BioTherapeutics (IMULAN) announced they have initiated a multi-site clinical trial to further assess the effect of Lymphocyte T-Cell Immunomodulator (LTCI) in cats with feline leukemia virus, a prevalent retroviral infections in domestic cats. LTCI is the first and only approved treatment aid in the United States for cats infected with feline leukemia virus (FeLV) and immunodeficiency virus (FIV) and the associated symptoms of lymphopenia, opportunistic infection, anemia, granulocytopenia, or thrombocytopenia.

Dr. Craig Woods, CEO of IMULAN, stated, "IMULAN has started the first in a series of studies to examine the effects of LTCI for feline leukemia virus. The first study will further characterize the clinical and immunological effects of this exciting new biologic for feline leukemia virus patients."

Dr. Craig Woods went on to state, "Lymphocyte T-Cell Immune Modulator is a potent regulator of lymphocyte production and function and has been shown to increase lymphocyte numbers and interleukin-2 production in animals. Lymphocytes and interleukin-2 play a pivotal role in eliciting an immune response against viruses. IMULAN believes this immunological approach will be far more effective than metabolic drug approaches, none of which are approved for feline viral infections."

About Feline Leukemia Virus (FeLV): Feline leukemia virus, a retrovirus, is an infectious disease of cats that often results in immune dysfunction and can be associated with certain forms of feline cancer, including leukemia and lymphoma. All retroviruses, including FeLV, feline immunodeficiency virus (FIV) and human immunodeficiency virus (HIV), produce an enzyme, reverse transcriptase, which permits them to insert copies of their own genetic material into host cells.

About Lymphocyte T-Cell Immunomodulator: LTCI is a conditionally approved treatment aid for cats infected with Feline Leukemia Virus (FeLV) and/or Feline Immunodeficiency Virus (FIV). Conditional licenses are granted by the United States Department of Agriculture Center for Veterinary Biologics to products that have met reasonable expectation of efficacy, have demonstrated purity, and passed safety testing. LTCI is manufactured by T-Cyte Therapeutics, Inc. and is exclusively distributed by IMULAN BioTherapeutics.

About IMULAN: IMULAN develops unique, precision immune regulating compounds for veterinary medicine. IMULAN's primary focus is on biological strategies that combine peptide pharmacology with immunology to treat infectious, autoimmune, and immune mediated diseases in small and large animal medicine. IMULAN recently commercialized Lymphocyte T-Cell Immunomodulator as a conditionally licensed treatment aid for cats infected with feline leukemia and immunodeficiency virus. For more information about IMULAN, please visit http://www.imulan.com

# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Craig Woods DVM, MS, MBA
Visit website